X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SP-2577 (seclidemstat) is an oral LSD1 inhibitor, small molecule drug candidate. It is being evaluated in phase 1 /2 clinical trials for the treatment of Ewing sarcoma.
Lead Product(s): Seclidemstat,Topotecan Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
SP-2577 (Seclidemstat) is an oral LSD1 inhibitor. It is being evaluated in phase 1 /2 clinical trials in combination with Azacitidine for the treatment of Hematologic Cancers.
Lead Product(s): Seclidemstat,Azacitidine
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
SP-3164 is an oral, next-generation molecular glue that uses deuterium-enabled chiral switching platform to stabilize the preferred (S)-enantiomer of avadomide, it has demonstrated clinical efficacy in non-Hodgkin Lymphomas and other hematologic malignancies.
Lead Product(s): SP-3164
Therapeutic Area: Oncology Product Name: SP-3164
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
The Company intends to use the net proceeds for further development of its product candidates, including SP 2577 (seclidemstat), a potent and orally bioavailable inhibitor of lysine-specific demethylase 1.
Lead Product(s): Seclidemstat,Azacitidine
Therapeutic Area: Oncology Product Name: SP 2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 16, 2023
Details:
The Company intends to use the net proceeds for further development of its product candidates, including SP 2577 (seclidemstat), a potent and orally bioavailable inhibitor of lysine-specific demethylase 1.
Lead Product(s): Seclidemstat,Azacitidine
Therapeutic Area: Oncology Product Name: SP 2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 12, 2023
Details:
SP-2577 (seclidemstat) is a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression currently being studied in Phase 1/2 clinical trials for the treatment of solid and hematologic cancers where LSD1 is implicated in disease progression.
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
SP-3164 is an oral, next-generation molecular glue that uses deuterium-enabled chiral switching platform to stabilize the preferred (S)-enantiomer of avadomide, it has demonstrated clinical efficacy in non-Hodgkin Lymphomas and other hematologic malignancies.
Lead Product(s): SP-3164
Therapeutic Area: Oncology Product Name: SP-3164
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
SP-2577 (seclidemstat) is a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression currently being studied in Phase 1/2 clinical trials for the treatment of solid and hematologic cancers where LSD1 is implicated in disease progression.
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2023
Details:
The funding will support Salarius Pharmaceuticals operations and development of its drug candidate SP-2577 (seclidemstat) for the treatment of Ewing sarcoma.
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cancer Prevention and Research Institute of Texas
Deal Size: $16.1 million Upfront Cash: Undisclosed
Deal Type: Funding February 16, 2023
Details:
SP-3164 is an oral molecular glue that uses deuterium-enabled chiral switching platform to stabilize the S-avadomide, which has demonstrated encouraging single-agent and combination-therapy clinical efficacy in NHL and other hematologic malignancies.
Lead Product(s): SP-3164
Therapeutic Area: Oncology Product Name: SP-3164
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
